Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

about

Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

Item

http://www.wikidata.org/entity/Q36896996

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Alemtuzumab-BEAM as conditioni ...... homa: a single-center analysis

@en

type

Item

label

Alemtuzumab-BEAM as conditioni ...... homa: a single-center analysis

@en

prefLabel

Alemtuzumab-BEAM as conditioni ...... homa: a single-center analysis

@en

P1476

Alemtuzumab-BEAM as conditioni ...... homa: a single-center analysis

@en

P2093

A Schulenburg

http://www.w3.org/2001/XMLSchema#string

C Sillaber

http://www.w3.org/2001/XMLSchema#string

H Greinix

http://www.w3.org/2001/XMLSchema#string

K Skrabs

http://www.w3.org/2001/XMLSchema#string

M Leiner

http://www.w3.org/2001/XMLSchema#string

M Mitterbauer

http://www.w3.org/2001/XMLSchema#string

P Kalhs

http://www.w3.org/2001/XMLSchema#string

U Jäger

http://www.w3.org/2001/XMLSchema#string

W Lamm

http://www.w3.org/2001/XMLSchema#string

W R Sperr

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.

Bone-marrow transplantation (first of two parts).

Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin's disease.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s.

P2888

s00432-016-2134-3

P304

1307-1314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00432-016-2134-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

142

http://www.w3.org/2001/XMLSchema#string

P50

Christian Schoergenhofer

Marija Bojic

Alexander Hermann

P Wohlfarth

P577

2016-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26920356

http://www.w3.org/2001/XMLSchema#string

P932

4865538

http://www.w3.org/2001/XMLSchema#string